– January 1, 2014
January 1, 2014
View Issues
-
Pancreatic Cancer Patients Live Longer when nab-Paclitaxel Is Added to Gemcitabine
It is indeed ironic that 16 years after the landmark Burris study, innovations in pancreatic cancer treatment still lack essential quality-of-life data. -
Change in CA19-9 after the First Cycle of second-line Pancreatic Cancer Treatment Predicts PFS and OS
Hopefully, as multi-institution, randomized trials are developed for second-line treatment of pancreatic cancer, CA19-9 levels will be included both pre- and post-first cycle treatment and responses compared with the established RECIST criteria. -
Identification of Prognostic Factors for Early Mortality in Treatment of Metastatic Colorectal Cancer
Calculating 60-day mortality risk by these readily available parameters (ECOG PS and WBC) can be used to identify high-risk patients who may require heightened surveillance after standard or experimental chemotherapy or, alternatively, a reduction in treatment intensity. -
Redefining the Natural History of Borderline Ovarian Tumors
This paper represents the largest collection of cases with central path review and provides better clarity to prognostic factors previously intimated from retrospective work.